We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 90

Health and environmental claims an ongoing bureau focus
  • Stikeman Elliott LLP
  • Canada
  • December 18 2007

Investigations and enforcement actions over marketing and advertising claims related to health products and services have been a significant part of the Bureau's recent fair-business-practices work


Health Canada Releases Annual Compliance and Enforcement Report for Fiscal Year 2015-2016
  • Stikeman Elliott LLP
  • Canada, USA
  • November 2 2016

In October 2016, the Consumer Product Safety Program (CPSP), a division of Health Canada, released its annual Compliance and Enforcement Report for


Bill C-17 (Vanessa’s Law) receives third reading
  • Stikeman Elliott LLP
  • Canada
  • October 24 2014

Bill C-17, An Act to Amend the Foods and Drugs Act (Vanessa's Law) has proceeded through the committee process without amendment and was read for a


Government seeks feedback on new drug safety initiatives
  • Stikeman Elliott LLP
  • Canada
  • May 6 2015

As previously reported, the Food and Drugs Act (the Act) has been substantively amended by Bill C-17, also known as Vanessa's Law; the Bill received


Competition Bureau sets out preliminary views on patent agreement settlement enforcement
  • Stikeman Elliott LLP
  • Canada
  • October 27 2014

On September 23, 2014, John Pecman, the Commissioner of Competition, delivered the keynote address at the George Mason University Pharma Conference


Court of Appeal clarifies - for utility the promise of the patent must be "clear and unambiguous"
  • Stikeman Elliott LLP
  • Canada
  • August 21 2013

On July 24, 2013, the Federal Court of Appeal (FCA) issued its decision in Apotex Inc. v. Sanofi-Aventis, overturning a Federal Court decision


Competition Bureau questions: Why don't we see more health care advertising?
  • Stikeman Elliott LLP
  • Canada
  • October 14 2016

Due to regulations by provincial governments and self-regulating professional bodies, Canadian health care professionals face significant


Proposed amendments to the Food and Drugs Act impose stricter after-market regulation on drugs and medical devices
  • Stikeman Elliott LLP
  • Canada
  • May 20 2014

The Minister of Health has introduced Bill C-17 An Act to Amend the Food and Drugs Act in the House of Commons, which is currently at the second


Health Canada announces wind turbine noise and health study
  • Stikeman Elliott LLP
  • Canada
  • July 12 2012

Health Canada announced Tuesday that it will be conducting a study on the health effects of low frequency noise generated by wind turbines on people who live nearby


Eli Lilly patent for atomoxetine for use in treating ADHD invalid for lack of utility
  • Stikeman Elliott LLP
  • Canada
  • October 19 2010

Novopharm Limited (now known as Teva Canada Limited but hereafter referred to as Novopharm) sought a declaration under s. 60(1) of the Patent Act, R.S.C. 1985, c. P-4 that Eli Lilly and Company’s (Lilly’s) Canadian Patent No. 2,209,735 (the ‘735 Patent) was invalid and void